

A POWERFUL PARTNERSHIP
FOR THE GMP MANUFACTURE
OF RECOMBINANT PROTEINS
PREVIOUSLY OUT OF REACH

Production of **RECOMBINANT PROTEINS** PREVIOUSLY OUT OF REACH

The use of conventional expression systems for recombinant production of many complex human glycoproteins is often limited by low titers, insufficient product quality or non-authentic glycosylation. CEVEC Pharmaceuticals' CAP-Go expression platform, a portfolio of glyco-optimized human suspension cell lines, addresses this need and enables the production of a broad range of difficult to express glycoproteins. Paragon Bioservices, your outsourcing partner for contract research and manufacturing services, and CEVEC now jointly offer high quality GMP manufacture of such proteins at industrial scale in North America.

CAP-Go features:

- Regulatory endorsed human high density suspension cells
- Panel of individual cell lines for tailor-made glycosylation of recombinant proteins
- Scalable and cost effective production in chemically defined serum free medium
- Optimal recombinant protein quality at high titers
- Excellent pharmacokinetics of CAP-Go derived therapeutic proteins

CEVEC and its preferred CDMO partner for North America, Paragon Bioservices, have the following joint offering for recombinant protein production in CAP-Go up to clinical phase 2:

- Cell line development
- Generation of master and working cell banks
- Process development
- GMP manufacturing
- Aseptic Fill/Finish

For further information please contact:

CEVEC Pharmaceuticals GmbH

Gottfried-Hagen-Str. 60-62 | 51105 Cologne | Germany
+49 (0)221 46020800 | info@cevec.com | www.cevec.com

Paragon Bioservices Inc.

Baltimore, MD | USA
+1 800 545 65 69 | +1 410 975 40 50 | www.paragonbioservices.com